Min-Chul Park
Direttore/Membro del Consiglio presso ZYVERSA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Min-Chul Park is the founder of Tme Therapeutics, Inc. He currently holds the position of Chief Executive Officer & Director at Curebio Therapeutics, Director at ZyVersa Therapeutics Operating, Inc., Independent Director at ZyVersa Therapeutics, Inc., and Assistant Professor at Inje University.
Previously, he served as Chief Executive Officer & Director at Neomics Co., Ltd., Chief Executive Officer & Director at CURE BIO Co., Ltd., and Senior Research Associate at Seoul National University.
He obtained his doctorate degree from Seoul National University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 21/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Min-Chul Park
| Società | Posizione | Inizio |
|---|---|---|
| ZYVERSA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/12/2022 |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Direttore/Membro del Consiglio | - |
| Inje University | Corporate Officer/Principal | - |
Precedenti posizioni note di Min-Chul Park
| Società | Posizione | Fine |
|---|---|---|
CURE BIO Co., Ltd.
 CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Amministratore Delegato | 01/04/2022 |
Neomics Co., Ltd.
 Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Amministratore Delegato | - |
Formazione di Min-Chul Park
| Seoul National University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ZYVERSA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
Neomics Co., Ltd.
Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
CURE BIO Co., Ltd.
CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Health Technology |
- Borsa valori
- Insiders
- Min-Chul Park
